Douglas Arbetter

653 total citations · 1 hit paper
13 papers, 363 citations indexed

About

Douglas Arbetter is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine and Physiology. According to data from OpenAlex, Douglas Arbetter has authored 13 papers receiving a total of 363 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Cardiology and Cardiovascular Medicine, 6 papers in Internal Medicine and 4 papers in Physiology. Recurrent topics in Douglas Arbetter's work include Atrial Fibrillation Management and Outcomes (6 papers), Venous Thromboembolism Diagnosis and Management (6 papers) and Asthma and respiratory diseases (4 papers). Douglas Arbetter is often cited by papers focused on Atrial Fibrillation Management and Outcomes (6 papers), Venous Thromboembolism Diagnosis and Management (6 papers) and Asthma and respiratory diseases (4 papers). Douglas Arbetter collaborates with scholars based in United States, Canada and United Kingdom. Douglas Arbetter's co-authors include Serge Korjian, Yazan Daaboul, C. Michael Gibson, Purva Jain, Robert A. Harrington, Samuel Z. Goldhaber, Adrian F. Hernandez, Russel Hull, Alex Gold and Gerald Chi and has published in prestigious journals such as Circulation, Blood and Clinical Infectious Diseases.

In The Last Decade

Douglas Arbetter

12 papers receiving 359 citations

Hit Papers

Efficacy and safety of intramuscular administration of ti... 2022 2026 2023 2024 2022 40 80 120
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial
    2022 127 citations Hugh Montgomery, Richard Hobbs et al. The Lancet Respiratory Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Douglas Arbetter United States 7 179 136 130 38 33 13 363
Vincent Mémier France 7 50 0.3× 52 0.4× 56 0.4× 28 0.7× 17 0.5× 9 201
Irfan Moinuddin United States 6 68 0.4× 99 0.7× 20 0.2× 105 2.8× 24 0.7× 14 272
Daniella A. Spittle United Kingdom 6 15 0.1× 52 0.4× 143 1.1× 18 0.5× 70 2.1× 12 269
Stacy Ellsworth United States 3 50 0.3× 163 1.2× 274 2.1× 42 1.1× 18 0.5× 4 360
Ashish Sule Singapore 7 55 0.3× 34 0.3× 26 0.2× 68 1.8× 43 1.3× 24 253
Shunsuke Kuroda Japan 11 193 1.1× 22 0.2× 63 0.5× 32 0.8× 29 0.9× 41 307
Abdallah Almaghraby Egypt 7 115 0.6× 14 0.1× 120 0.9× 64 1.7× 30 0.9× 76 313
Rahim Kanji United Kingdom 9 63 0.4× 41 0.3× 67 0.5× 42 1.1× 18 0.5× 18 217
Abigail Chan United States 6 25 0.1× 22 0.2× 127 1.0× 18 0.5× 29 0.9× 17 236
Brent Muhlestein United States 4 241 1.3× 40 0.3× 26 0.2× 91 2.4× 19 0.6× 5 408

Countries citing papers authored by Douglas Arbetter

Since Specialization
Citations

This map shows the geographic impact of Douglas Arbetter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas Arbetter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas Arbetter more than expected).

Fields of papers citing papers by Douglas Arbetter

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas Arbetter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas Arbetter. The network helps show where Douglas Arbetter may publish in the future.

Co-authorship network of co-authors of Douglas Arbetter

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas Arbetter. A scholar is included among the top collaborators of Douglas Arbetter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas Arbetter. Douglas Arbetter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
2.
Arbetter, Douglas, Vancheswaran Gopalakrishnan, Anastasia A. Aksyuk, et al.. (2024). Lower Respiratory Tract Infections Following Respiratory Syncytial Virus Monoclonal Antibody Nirsevimab Immunization Versus Placebo: Analysis From a Phase 3 Randomized Clinical Trial (MELODY). Clinical Infectious Diseases. 81(3). 634–644. 6 indexed citations
3.
Jackson, David J., Girolamo Pelaia, Benjamin Emmanuel, et al.. (2024). Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme. European Respiratory Journal. 64(1). 2301521–2301521. 28 indexed citations
4.
Jackson, D.A., Girolamo Pelaia, Alicia Padilla‐Galo, et al.. (2023). Asthma Clinical Remission with Benralizumab in an Integrated Analysis of the Real-World XALOC-1 Study. Journal of Allergy and Clinical Immunology. 151(2). AB13–AB13. 5 indexed citations
5.
Penz, Erika, Thomas Rothe, Lieven Dupont, et al.. (2023). Early Asthma Control Improvement with Benralizumab: 8-Week Interim Integrated Analysis from the Real-World XALOC-2 Study. Journal of Allergy and Clinical Immunology. 151(2). AB13–AB13. 1 indexed citations
6.
Montgomery, Hugh, Richard Hobbs, Francisco Padilla, et al.. (2022). Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet Respiratory Medicine. 10(10). 985–996. 127 indexed citations breakdown →
7.
Gibson, C. Michael, Serge Korjian, Gerald Chi, et al.. (2017). Comparison of Fatal or Irreversible Events With Extended‐Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. Journal of the American Heart Association. 6(7). 34 indexed citations
8.
Arbetter, Douglas, Purva Jain, Megan K. Yee, et al.. (2017). Competing risk analysis in a large cardiovascular clinical trial: An APEX substudy. Pharmaceutical Statistics. 16(6). 445–450. 7 indexed citations
9.
10.
11.
Gibson, C. Michael, Rim Halaby, Serge Korjian, et al.. (2016). The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial. American Heart Journal. 185. 93–100. 39 indexed citations
12.
Gibson, C. Michael, Gerald Chi, Rim Halaby, et al.. (2016). Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients. Circulation. 135(7). 648–655. 50 indexed citations
13.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vincent Mémier Breakdown of academic impact, for papers by Irfan Moinuddin Breakdown of academic impact, for papers by Daniella A. Spittle Breakdown of academic impact, for papers by Stacy Ellsworth Breakdown of academic impact, for papers by Ashish Sule Breakdown of academic impact, for papers by Shunsuke Kuroda Breakdown of academic impact, for papers by Abdallah Almaghraby Breakdown of academic impact, for papers by Rahim Kanji Breakdown of academic impact, for papers by Abigail Chan Breakdown of academic impact, for papers by Brent Muhlestein
Rankless by CCL
2026